Clinical trials: Hair Problems
Hair Thinning
To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair
The purpose of this multi-site, double-blind, placebo-controlled clinical study, conducted for Lifes2Good, is to evaluate certain physiological effects of Viviscal Oral Supplement compared to a placebo in female subjects with…
- Trial name
- NCT02288858
- Testing
- Viviscal Oral Supplement Tablets
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Irish Response t/a Lifes2good
Alopecia, Alopecia, Androgenetic
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT02676310
- Testing
- Bimatoprost
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Allergan
Hair Thinning
Efficacy and Tolerability of a Scalp Serum
The goal of this clinical trial is to evaluate the efficacy and tolerability of a scalp serum on 60 healthy females aged 25 to 65 years with Fitzpatrick skin phototypes I-VI and with mild to moderate thinning hair.
- Trial name
- NCT07500623
- Testing
- Scalp Serum
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Revision Skincare
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Alopecia Areata
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03941548
- Testing
- CTP-543
- Where
- 12 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Concert Pharmaceuticals
Androgenetic Alopecia
Photosensitization Study in Androgenetic Alopecia
This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)
- Trial name
- NCT02791243
- Testing
- Finasteride 0.25%, Negative Control
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Polichem S.A.
SARS-CoV 2, COVID
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS).
- Conditions
- SARS-CoV 2, COVID, COVID-19, Androgenetic Alopecia
- Trial name
- NCT04368897
- Testing
- CAG length <22, CAG length >=22
- Where
- Spain
- Sponsor
- Applied Biology, Inc.
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Androgenetic Alopecia, Pattern Baldness
Evaluation of the Niostem Headset for Hair Growth and Hair Quality
This double-blind, randomized, placebo-controlled clinical trial evaluates the Niostem headset, an electronic device designed to support hair growth, reduce hair loss, and improve hair quality.
- Trial name
- NCT06994819
- Testing
- niostem headset (Active)
- Where
- Germany
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Mane Biotech GmbH
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Hair Loss
Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women.
- Trial name
- NCT07556016
- Testing
- Active nutricosmetic
- Where
- 4 sites in France
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Severe Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body.
- Trial name
- NCT07772492
- Testing
- Upadacitinib
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- AbbVie
Androgenetic Alopecia
Phase III Study of KX-826 With Adult Male Patients With AGA
This is a phase III, multi-center, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of KX-826 for topical use in Chinese adult male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06126965
- Testing
- KX-826-（5%） BID
- Where
- 26 sites in China
- Volunteers
- 740 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia Areata(AA)
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
This study includes a dose escalation part(phase I) and a dose extension part(phase II).
- Trial name
- AA (NCT04445363)
- Testing
- Jaktinib hydrochloride cream
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hair Loss
Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser
The study incudes 18 to 55 y/o healthy subjects with moderate hair loss stage and Fitzpatrick skin type 5 or 6
- Trial name
- NCT06885112
- Testing
- FoLix treatment for improving the scalp hair appearance
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Male Pattern of Hair Loss, Androgenic Alopecia
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
- Trial name
- NCT02460289
- Testing
- Treatment: Minoxidil 5% / Botanical Hair Solution for Men
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Hair Thinning
Clinical Study to Evaluate the Impact of Nutraceutical Supplements in Participants With Self-Perceived Thinning Hair
The purpose of the study is to determine changes in biomarkers associated with hair loss and scalp microbiome with a novel botanical formulation
- Trial name
- NCT07901062
- Testing
- Nutraceuticals (Prototype)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Unilever R&D
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)
The purpose of this study is to evaluate the ability of injections of Ji Gami(TM) N and Ji Gami(TM) NDO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451138
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Clinical Trial in Females for Female Pattern Hair Loss
This is a six month clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a 5% minoxidil topical foam (MTF) formulation applied once a day versus a topical foam vehicle…
- Trial name
- NCT01226459
- Testing
- 5% Minoxidil Topical Foam, Vehicle Topical Foam
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 404 people
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Hair Thinning
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using XVIE solution applied on the scalp of women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07221773
- Testing
- XVIE
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé